Summary

Overview
Global HIV Rapid Test Kits Market reached US$ XX billion in 2022 and is expected to reach US$ XX billion by 2030 growing with a CAGR of XX% during the forecast period 2023-2030.
A rapid HIV test is useful for the detection of HIV at a faster rate usually in less than 30 minutes. It is a simple test to determine the antibodies in the oral fluids like blood and urine. HIV testing took a drastic shift from normal testing by drawing blood which takes a lot of time to rapid antigen testing which takes less than 30 minutes.
The test determines the type 1 HIV or type 2 which is dependent on the antigen present on the virus molecule. This is called differential detection. Although the results are faster, the accuracy of the standard tests is higher than the rapid ones.
Dynamics
Rising prevalence of HIV-related cases
The worldwide incidence of HIV is high and is increasing at a very fast pace. For instance, according to the World Health Organization, the prevalence of HIV worldwide is very high with 39 million people living with it in 2022. Approximately 6,30,000 people die due to HIV-related illness in 2022. Women who are living with HIV are more with 20 million cases, men with 17.4 million, and children with 1.5 million cases in 2022. African regions are the most severely affected region with nearly 1 in every 25 adults living with HIV which accounts for more than two-thirds of the people living with HIV worldwide.
According to our World in Data Organization, 2023, over 1.5 % of deaths are caused by HIV globally which is more in lower-income countries like Africa due to the unavailability of disease diagnosis and treatment.
Furthermore, according to the UNICEF organization, as of 200 more than 14 children under the age of 18 lost one or both parents due to HIV and other AIDS-related causes. The epidemics are common in low-income country regions due to limitations in the diagnosis and treatment options for deadly diseases like HIV.
Inaccuracy of rapid test results
Point-of-care tests have a high rate of false negative and false positive results. As the results are produced within no time, there is high sensitivity. Although the test results are accurate, false positives and false negatives are possible which can lead to severe complications. According to the National Institute of Health, 2023, misdiagnosis of HIV using rapid test kits is prevalent by about 3.1% and false positive and false negative results are about 0.4%. The rapid test should be always followed by a standard HIV test due to its accuracy.
Segment Analysis
The global HIV rapid test kits are segmented based on technology, specimen, disease Type, distribution channel and region.
The lateral immuno assay Segment Accounted for Approximately 45.3% of the Market Share
Rapid enzyme immunoassays are the most commonly used for HIV screening tests. These enzyme immunoassays are rapid and can be used easily for the detection of HIV infection. The result is out quickly, within 30 minutes of usage which makes it more sensitive, rapid, and accurate and it can be easily used in home care settings. It detects the antibodies in the serum and provides accurate results hence, approved by the FDA. These are available in the form of small kits which makes them handy and portable. The launch of HIV rapid test kits increased due to the demand for these kits in the market.
For instance, in February 2023, Mylab launched new rapid test kits for the detection of HIV and other sexually transmitted diseases like hepatitis and syphilis.
In February 2022, the Thai Red Cross launched rapid-acting self-test kits to detect HIV. These kits are designed to combat social stigma around the diagnosis of HIV and its treatment.
Geographical Analysis
North America accounted for Approximately 42.7% of the Market Share in 2022
North America is expected to hold the largest share of the market due to the high incidence of HIV infections in the US and Canada.
According to the U.S. Department of Health & Human Services, 2023, nearly 1.2 million people in the U.S. are suffering from HIV infection. About 13% are undiagnosed and left untreated. In 2021, there were 32,100 estimated new HIV infections in the U.S. and the rate was 11.5 (per 100,000 people).
In March 2023, according to the Oxford Academic Journal, 2023, individuals with 15-29 account for more than 1 quarter of new HIV cases in Canada.
COVID-19 Impact Analysis
COVID-19 impacted the HIV rapid test market due to an increase in the focus on COVID-19 treatment. The shift in the focus has decreased the diagnosis followed by the treatment of HIV. Several hospitals have seen a decrease in patient visits during the peak of the pandemic. The demand for rapid HIV self-tests decreased and shifted toward the covid 19 treatment.
Due to the rise in cases during the midst of the pandemic, there is the postponement of the diagnosis of deadly diseases like HIV, cancer, etc. The research and development on HIV halted, which impacted the advancements of test kits. However, after the COVID-19 infection came under control, rise in the focus on sectors like oncology and infectious diseases increased.
By Technology
• Lateral Flow Immunoassay
• Immunofiltration
By Specimen
• Blood
• Urine
• Oral Fluid
By Disease Type
• HIV Type 1
• HIV Type 2
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In November 2022, Abbott launched new HIV home test kit, Panbio HIV Self-Test which is available over the counter which show the results within 20 minutes.
• In March 2023, Emory University launched a program to deliver 1 million rapid HIV self-tests across the country to raise awareness about HIV among people.
Competitive Landscape
The major global players in the HIV rapid test kits market include Biolytical Laboratories, Meril Life Sciences Pvt. Ltd., JOYSBIO (Tianjin) Biotechnology Co., Ltd, Alpine Biomedicals Pvt Ltd., Abbott Laboratories, Sedia Biosciences Corporation., Trivitron Healthcare, XIAMEN BOSON BIOTECH CO., LTD, F. Hoffmann-La Roche Ltd, and Viatris Inc. among others.
Why Purchase the Report?
To visualize the global HIV rapid test kits market based on technology, specimen, disease type, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of HIV rapid test kits market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global HIV rapid test kits market report would provide approximately 65 tables, 65 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Technology
3.2. Snippet by Specimen
3.3. Snippet by Disease Type
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising prevalence of HIV-related cases
4.1.2. Increasing incidence of autoimmune diseases
4.1.3. Restraints
4.1.3.1. Inaccuracy of rapid test results
4.1.4. Opportunity
4.1.5. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Epidemiology Statistics
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Technology
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
7.1.2. Market Attractiveness Index, By Technology
7.2. Lateral Flow Immunoassay*
7.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
7.2.2. Market Attractiveness Index, By Technology
7.3. Immunofiltration
8. By Specimen
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Specimen
8.1.2. Market Attractiveness Index, By Specimen
8.2. Blood
8.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Specimen
8.2.2. Market Attractiveness Index, By Specimen
8.3. Urine
8.4. Oral Fluid
9. By Disease Type
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.1.2. Market Attractiveness Index, By Disease Type
9.2. HIV Type 1
9.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.2.2. Market Attractiveness Index, By Disease Type
9.3. HIV Type 2
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacies
10.4. Online Pharmacies
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Specimen
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Specimen
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Russia
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Specimen
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Specimen
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Specimen
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Biolytical Laboratories
13.1.1. Company Overview
13.1.2. Technology Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Meril Life Sciences Pvt. Ltd.
13.3. JOYSBIO (Tianjin) Biotechnology Co., Ltd
13.4. Alpine Biomedicals Pvt Ltd.
13.5. Abbott Laboratories
13.6. Sedia Biosciences Corporation.
13.7. Trivitron Healthcare
13.8. XIAMEN BOSON BIOTECH CO., LTD
13.9. F. Hoffmann-La Roche Ltd
13.10. Viatris Inc.
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us